News and Trends 19 Dec 2022 Watch: Adrenomed tackling huge issue of sepsis Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead […] December 19, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer OmniSpirant Limited and EVerZom have launched INSPIRE, a €12.8 million ($13.4 million) lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant and its European partners in biotechnology, medical devices, cancer research, academia and patient advocacy, met in Galway, Ireland, for the official kick-off […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2022 Partnership to deliver oncology workflow for 7 European hospitals A BC Platforms (BCP) partnership that includes Finland’s Euformatics and Hungary’s Oncompass Medicine has been awarded a contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven European hospitals, represented by the Medical University Graz. The consortium is formed by hospitals from the Medical University of Graz in Austria, […] December 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2022 Creating designer immune cells at scale To prevent testing on animals and create more precise ways of testing therapeutics, the pharmaceutical industry is turning to human immune cells. However, the availability of cells has been limited to date. Now, researchers at the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) and Hannover Medical School (MHH) in Germany have succeeded in scaling […] December 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2022 New function of CRISPR gene scissors discovered For several years, the CRISPR/Cas9 gene scissors have been causing a sensation in science and medicine. Researchers from the Institute of Structural Biology at the University Hospital Bonn (UKB) in Germany and the Medical Faculty of the University of Bonn, in cooperation with the partner University of St Andrews in Scotland and the European Molecular […] November 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 23 Nov 2022 What recent mixed clinical results can teach about Alzheimer’s disease 2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a treatment to slow the progression of Alzheimer’s disease has endured decades of disappointments. The most common treatment strategy — clearing up harmful deposits, or “plaques,” […] November 23, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Concern as study says new covid sub-variant is resistant to all therapeutic antibodies All approved antibody therapies for Covid-19 are ineffective against the Omicron sub-lineage BQ.1.1. That’s the worrying news following a recent study by researchers at the German Primate Center (DPZ) – Leibniz Institute for Primate Research and Friedrich-Alexander University Erlangen-Nürnberg. Omicron sub-variant BQ.1.1 is currently on the rise worldwide. As a result of an infection with […] November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022 CatalYm raises €50M to boost solid tumors trial CatalYm has announced the close of a €50 million ($49 million) series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the clinical development of its […] November 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics This week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio. We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. […] November 18, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 FundaMental Pharma launches with €10M to advance first-in-class neuroprotectant FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University in Germany, has launched with €10 million ($10.4 million) in seed financing. The funding was led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech Gründerfonds (HTGF). Built on the research of Hilmar Bading and Jing […] November 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 InfanDx tackles early detection of hypoxic ischemic encephalopathy InfanDx AG, a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, has completed the validation of metabolic biomarker panels for the early detection of hypoxic ischemic encephalopathy (HIE) in newborns. The validated biomarkers of such panels will be the target of the company’s HypoxE blood test for […] November 14, 2022 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email